NCT03011372

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 47 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of pemigatinib (INCB054828) in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1 rearrangement.

Conditions

• MPN (Myeloproliferative Neoplasms)

Interventions

Type	Name	Description
DRUG	Pemigatinib	Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy. Participants will receive either the intermittent dose (as written) or continuous dosing.

Timeline

• Start date: 2017-04-25
• Primary completion: 2024-10-30
• Completion: 2024-10-30
• First posted: 2017-01-05
• Last updated: 2025-11-18
• Results posted: 2025-11-18

Locations

33 sites across 11 countries: United States, Austria, Belgium, Canada, France, Germany, Italy, Japan, Spain, Switzerland, United Kingdom

Regulatory

• FDA-regulated drug study